In vivo pharmacokinetics of a gentamicin-loaded collagen sponge in acute periprosthetic infection - Serum values in 19 patients

Background The in vivo pharmacokinetics of gentamycin- loaded collagen fleeces in humans have not been described in the current literature. We therefore analyzed in vivo pharmacokinetics of these fleeces when used in the treatment of periprosthetic infections. Patients and methods Gentamycin concentrations were measured in 19 consecutive patients with an acute periprosthetic infection. Each patient received 2-5 fleeces (130 mg gentamycin/fleece). Results Initially, the blood concentration increased to 3.2-7.2 mg/L, depending on the number of fleeces that were applied. The serum peak concentrations resulted in peak/MIC ratios of 2.5-36 for P. aeruginosa, S. aureus, and Klebsiella spp. Subsequently, the serum values decreased almost linearly below 0.3 mg/L in 18 to 62 hours. After 24 hours, the serum levels of gentamicin dropped below 2 mg/L, the toxicity threshold. Interpretation The application of 2 to 5 130-mg gentamycin-loaded collagen fleeces may be useful as an adjuvant treatment for implant-related infections, since no toxic concentrations were measured 24 hours postoperatively

Burden of early, advanced and metastatic breast cancer in The Netherlands

BACKGROUND: The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands. METHODS: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health related burden of breast cancer for overall, DCIS (stage 0), early- (stage I), locally advanced- (stage II-III) and metastatic- (stage IV) breast cancer by age groups and by year (if applicable). RESULTS: The overall incidence of breast cancer increased from 103.4 up to 153.2 per 100,000 women between 1990 and 2014. The increase was driven by DCIS and early breast cancer as the incidence of locally advanced and metastatic breast cancer remained stable. Between 1990 and 2014, ten-year overall survival rates increased from 87% to 93% for early breast cancer, 41% to 62% for locally advanced- and from 6% to 9% for metastatic disease. Annually, breast cancer in the Netherlands is responsible for approximately 3100 deaths, 26,000 life years lost, 65,000 Disability Adjusted Life Years (DALYs) and an economic burden of €1.27 billion. CONCLUSIONS: This study provides a comprehensive assessment of the burden of breast cancer and subsequent trends over time in the Netherlands